This is the text extract for Funding proposal for clindamycin, sulphasalazine, cabergoline and medroxyprogesterone. Closed, browse documents here.

---

29 October 2009

Funding proposal for clindamycin (Dalacin C), sulphasalazine (Salazopyrin), cabergoline (Dostinex) and medroxyprogesterone

PHARMAC is seeking feedback on a proposal to amend the prices and subsidies for clindamycin (Dalacin C), cabergoline (Dostinex), sulphasalazine (Salazopyrin and Salazopyrin EN) and various medroxyprogesterone preparations through a provisional agreement with Pfizer New Zealand Limited. The proposed changes would occur from 1 January 2010, except for sulphasalazine which would occur from 1 March 2010. In summary, it is proposed that: · the prices and subsidies would be reduced for clindamycin injections (Dalacin C) and cabergoline tablets (Dostinex); the prices and subsidies would be increased for sulphasalazine tablets (Salazopyrin and Salazopyrin EN). Sulphasalazine tablets would also be listed in Section H of the Pharmaceutical Schedule; the prices and subsidies would be amended for various medroxyprogesterone acetate preparations (Provera and Depo-Provera). Medroxyprogesterone acetate (Depo-Provera) would also be listed in Section H of the Pharmaceutical Schedule; and the above brands would have various periods of subsidy and/or delisting protection and/or be awarded Hospital Supply Status.

·

·

·

Further details of the proposal can be found on the following pages. Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Thursday, 12 November 2009 to: Greg Williams Therapeutic Group Manager PHARMAC Email: greg.williams@pharmac.govt.nz Fax: 04 460 4995 Post: PO Box 10 254 Wellington 6143

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. A316960 Page 1 of 3

---

Details of the proposal Clindamycin Injection · The price and subsidy (ex-manufacturer, excluding GST) for clindamycin injection (Dalacin C) would be reduced in Section B and in Section H of the Pharmaceutical Schedule from 1 January 2010 as follows:

Pack size 1 Current price and subsidy $19.45 Proposed Price and subsidy $16.00

Chemical

Formulation Inj phosphate 150 mg per ml, 4 ml

Brand

Clindamycin

Dalacin C

·

Dalacin C would have Hospital Supply Status and protection from delisting and subsidy reduction until 1 July 2013.

Cabergoline · The prices and subsidies (ex-manufacturer, excluding GST) for cabergoline tablets (Dostinex) would be reduced in Section B of the Pharmaceutical Schedule from 1 January 2010 as follows:

Current price and subsidy $26.26 $105.03 Proposed Price and subsidy $16.50 $66.00

Chemical Cabergoline Cabergoline

Formulation Tab 0.5 mg Tab 0.5 mg

Brand Dostinex Dostinex

Pack size 2 8

·

Dostinex would have protection from delisting and subsidy reduction until 1 July 2012.

Sulphasalazine · The prices and subsidies (ex-manufacturer, excluding GST) for sulphasalazine tablets (Salazopyrin and Salazopyrin EN) would be increased in Section B of the Pharmaceutical Schedule from 1 March 2010 as follows:

Current price and subsidy $8.42 $9.44 Proposed Price and subsidy $11.68 $12.89

Chemical Sulphasalazine Sulphasalazine

Formulation Tab 500 mg Tab 500 mg enteric coated

Brand Salazopyrin Salazopyrin EN

Pack size 100 100

·

Salazopyrin and Salazopyrin EN would be listed in Section H of the Pharmaceutical Schedule from 1 March 2010 at the above proposed prices. Salazopyrin and Salazopyrin EN would have protection from delisting and subsidy reduction until 1 July 2013.

·

A316960T09-376

Page 2 of 3

---

Medroxyprogesterone acetate · The price and subsidy (ex-manufacturer, excluding GST) for medroxyprogesterone acetate (Depo-Provera) would be reduced in Section B of the Pharmaceutical Schedule from 1 January 2010 as follows:

Current price and subsidy $8.05 Proposed Price and subsidy $7.15

Chemical Medroxyprogesterone acetate

Formulation Inj 150 mg per ml, 1 ml

Brand DepoProvera

Pack size

1

·

Medroxyprogesterone acetate injection (Depo-Provera) would be listed in Section H of the Pharmaceutical Schedule from 1 January 2010 at the above proposed prices. The prices and subsidies (ex-manufacturer, excluding GST) for medroxyprogesterone acetate (Provera) would be amended in Section B and in Section H of the Pharmaceutical Schedule from 1 January 2010 as follows:

Current price and subsidy $2.07 $13.75 $7.57 $104.26 $78.06 Proposed Price and subsidy $3.09 $13.06 $6.85 $96.50 $70.50

·

Chemical Medroxyprogesterone acetate Medroxyprogesterone acetate Medroxyprogesterone acetate Medroxyprogesterone acetate Medroxyprogesterone acetate

Formulation

Brand

Pack size

Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 100 mg Tab 200 mg

Provera Provera Provera Provera Provera

30 100 30 100 30

·

Provera and Depo-Provera would each have Hospital Supply Status and protection from delisting and subsidy reduction until 1July 2013.

Background This proposal is the result of Pfizer New Zealand Limited submitting to PHARMAC an commercial proposal as an alternative to tendering. A request for alternative commercial proposals was made to all pharmaceutical suppliers on 21 August 2009 as part of the consultation on the proposed 2009/10 Multi-product Tender. Medroxyprogesterone acetate and clindamycin injections were proposed for inclusion in the 2009/10 Multi-product Tender; if this proposal is approved they will not be included.

A316960T09-376

Page 3 of 3